FB817-NHCC-Sessions_703.jpg

Cumberland Pharmaceuticals CEO A.J. Kazimi

 Photo: NHCC

The stock of Cumberland Pharmaceuticals will seek a major recalibration Tuesday after the company's announcement that it is seeking U.S. Food and Drug Administration (FDA) approval for a new drug.

Despite the news of the next step to bring a rare treatment to the market, Cumberland stock lost nearly half its value during the week’s first trading session following the release of the drug trial report.